Expertise in
18
conditions

Dr. Musaberk Goksel

Central Peninsula General Hospital Inc
Soldotna, AK
Expertise in
18
conditions
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
Offers Telehealth
36 Years of Experience
Expertise in
18
conditions
OverviewInsuranceLocationsClinical Research

Overview

Musaberk Goksel is a Hematologist Oncology specialist and a Hematologist in Soldotna, Alaska. Dr. Goksel has been practicing medicine for over 36 years is highly rated in 18 conditions, according to our data. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Non-Small Cell Lung Cancer (NSCLC). Dr. Goksel is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1989
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in AK
Hospital Affiliations
South Peninsula Hospital
Central Peninsula General Hospital
Languages Spoken
English
Portuguese
Turkish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Premera
  •  Moda Health
  •  CareSource

Locations

CENTRAL PENINSULA GENERAL HOSPITAL INC
250 Hospital Pl, Soldotna, AK 99669
907-714-4515

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

QUILT 2.023: A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803, in Combination With Current Standard of Care VS Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic NSCLC.
QUILT 2.023: A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803, in Combination With Current Standard of Care VS Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic NSCLC.
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2024
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 2 Less Clinical Trials

1 Total Publications

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Journal: The Lancet. Oncology
Published: January 22, 2021
Similar Doctors
Expertise in
22
conditions
Dr. David S. Eilender
Hematology Oncology | Hematology | Oncology
Expertise in
22
conditions
Dr. David S. Eilender
Hematology Oncology | Hematology | Oncology

Central Peninsula General Hospital Inc

240 Hospital Pl, 
Soldotna, AK 
 (0.1 mi)
907-262-7795
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Eilender is a Hematologist Oncology specialist and a Hematologist in Soldotna, Alaska. Dr. Eilender is highly rated in 22 conditions, according to our data. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Eilender is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile